Drug Profile
Visilizumab - PDL BioPharma
Alternative Names: Anti-CD3 monoclonal antibody humanised - Protein Design Labs; HuM-291; Humanised anti-CD3 IgG2 antibody HuM291 gamma-2M3; Humanised monoclonal antibody M291; Monoclonal antibody anti-CD3 humanised; Nuvion; SMART anti-CD3 antibody; SMART anti-CD3 MAb; VisiluzumabLatest Information Update: 21 Jun 2021
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Graft-versus-host disease; Psoriasis; Renal transplant rejection; Ulcerative colitis
Most Recent Events
- 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in Canada (IV)
- 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in Europe (IV)
- 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in USA (IV)